新冠疫苗合作国际论坛联合声明(中英对照)

Joint Statement of the International Forum on COVID-19 Vaccine Cooperation

Jointly launched by Argentina, Brazil, Chile, China, Colombia, the Dominican Republic, Ecuador, Egypt, Hungary, Indonesia, Kenya, Malaysia, Mexico, Morocco, Pakistan, the Philippines, Serbia, South Africa, Sri Lanka, Thailand, Turkey, the United Arab Emirates and Uzbekistan at the first meeting of the International Forum on COVID-19 Vaccine Cooperation on August 5, 2021.

1. We recognize that solidarity and cooperation are key to fighting against the COVID-19 pandemic, a challenge confronting all countries in the world. We must champion the vision of building a global community of health for all, put people and their lives first and make concerted and coordinated efforts to address the challenge.

2. We recognize the importance of COVID-19 vaccination as a global public good, and call upon all parties to step up efforts to make vaccines more accessible and affordable in developing countries, including making utmost efforts to provide vaccines for developing countries, LDCs in particular.

3. We call upon all countries, in cooperation with the relevant stakeholders, to increase national, regional and global capacities, carry out vaccine research and development as well as production in line with strict standards according to the World Health Organization (WHO) regulations, and provide safe, effective and high-quality COVID-19 vaccines.

4. We support the WHO in promoting access to COVID-19 vaccines through the Access to COVID-19 Tools (ACT) Accelerator and its COVAX Facility, encourage capable vaccine-producing countries to provide more vaccines to COVAX, and call upon multilateral financial institutions and other international organizations to provide inclusive financial support for vaccine procurement and for strengthening production capabilities in developing countries.

5. We underline the importance of vaccine multilateralism and call upon countries to enhance international cooperation mechanisms and collaboration, reject vaccine nationalism, lift export restrictions on relevant vaccines and raw materials, support enhanced cooperation on vaccine research and development, production, equitable distribution and ensure cross-border flows of vaccines.

6. We call upon countries to encourage the ongoing consideration on possible waiver of intellectual property rights for COVID-19 vaccines at the World Trade Organization, stressing the need for flexibility, pragmatism and a sense of urgency. We encourage countries to further strengthen international cooperation on vaccine production capacity by conducting joint research and development, authorized production and technology transfers, and continue to adopt concrete measures to raise the vaccine production capacity of developing countries.

7. We emphasize the scientific nature and importance of World Health Organization Emergency Use List, and call on governments, while conducting study on easing national entry regulations for the vaccinated, to follow the principle of fairness, equity, science and non-discrimination, respect the suggestions proposed by the WHO based on this principle, and strengthen communication and coordination on vaccine certification and regulation policies.

8. We hear the report by the representatives of the vaccine companies and welcome their cooperation outcomes achieved. We are determined to take further joint actions to engage companies and all stakeholders and support their participation in international cooperation efforts on increasing vaccine production and distribution, jointly promote fair, affordable, timely, universal and equitable distribution and strengthen local production of vaccines around the world, and welcome more partners to come aboard, including through transfer of technology.

新冠疫苗合作国际论坛联合声明

阿根廷、巴西、智利、中国、哥伦比亚、多米尼加、厄瓜多尔、埃及、匈牙利、印度尼西亚、肯尼亚、马来西亚、墨西哥、摩洛哥、巴基斯坦、菲律宾、塞尔维亚、南非、斯里兰卡、泰国、土耳其、阿联酋和乌兹别克斯坦，于2021年8月5日在新冠疫苗合作国际论坛首次会议期间，共同发表联合声明。

一、我们认为新冠肺炎疫情大流行是全球面临的共同挑战，应秉持人类卫生健康共同体理念，坚持人民至上、生命至上，团结协作应对疫情挑战。

二、我们强调新冠疫苗作为全球公共产品的重要意义，呼吁各方为实现疫苗在发展中国家的可及性和可负担性继续努力，尽可能向发展中国家特别是最不发达国家提供疫苗。

三、我们呼吁世界各国与利益攸关方合作，增加国家、区域和全球疫苗研发和生产，根据世界卫生组织要求，以严格标准开展疫苗研发和生产，提供安全、有效、高质量的新冠疫苗。

四、我们支持世界卫生组织通过“新冠疫情应对工具加速计划”及其“新冠疫苗实施计划”获得疫苗，鼓励有条件的疫苗生产国向“新冠疫苗实施计划”提供更多疫苗，呼吁多边金融机构和其他国际组织为发展中国家采购疫苗、提高疫苗生产能力提供包容性融资支持。

五、我们强调疫苗多边主义的重要性，呼吁各国增强国际合作机制与协作，摒弃“疫苗民族主义”，解除有关疫苗和原材料的出口限制，包括通过技术转让等方式，支持本国企业开展疫苗研发、生产、公平分配等国际合作，确保疫苗跨境运输畅通。

六、我们呼吁各方支持世界贸易组织继续推进新冠疫苗知识产权豁免，强调需要展现灵活性、务实性和紧迫性。我们鼓励各国通过开展联合研发、授权生产和技术转让等方式进一步加强疫苗产能国际合作，继续采取具体措施提升发展中国家疫苗产能。

七、我们强调世界卫生组织紧急使用清单制度的科学和重要性，呼吁各国政府在研究放松对疫苗接种者入境管控措施时，采取公平、合理、科学、非歧视性原则，尊重世界卫生组织根据此原则提出的建议，并加强疫苗认证和监管政策沟通协调。

八、我们听取了疫苗企业代表的报告，欢迎他们取得的合作成果。我们决心进一步采取共同行动，与企业和利益攸关方接触，并支持他们参与疫苗国际合作，增加疫苗产量，提升本地生产能力，共同促进全球疫苗公平、可负担、及时、普遍、合理分配，欢迎更多伙伴加入。